NZ502874A - Antihyperlipidemic statin-lp(a) inhibitor combinations - Google Patents

Antihyperlipidemic statin-lp(a) inhibitor combinations

Info

Publication number
NZ502874A
NZ502874A NZ502874A NZ50287498A NZ502874A NZ 502874 A NZ502874 A NZ 502874A NZ 502874 A NZ502874 A NZ 502874A NZ 50287498 A NZ50287498 A NZ 50287498A NZ 502874 A NZ502874 A NZ 502874A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutically acceptable
statin
pharmaceutical composition
kit
acceptable salt
Prior art date
Application number
NZ502874A
Other languages
English (en)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Amharack
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ502874A publication Critical patent/NZ502874A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ502874A 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations NZ502874A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
PCT/US1998/023480 WO1999030706A1 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS

Publications (1)

Publication Number Publication Date
NZ502874A true NZ502874A (en) 2004-03-26

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502874A NZ502874A (en) 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations

Country Status (14)

Country Link
EP (1) EP1037623A1 (ja)
JP (1) JP2003524582A (ja)
KR (1) KR20010033017A (ja)
AU (2) AU1306099A (ja)
BR (1) BR9813539A (ja)
CA (1) CA2299397A1 (ja)
HU (1) HUP0100349A3 (ja)
IL (1) IL134364A0 (ja)
IS (1) IS5385A (ja)
NO (1) NO20002965L (ja)
NZ (1) NZ502874A (ja)
PL (1) PL343851A1 (ja)
WO (1) WO1999030706A1 (ja)
ZA (1) ZA9811349B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
ES2227115T5 (es) * 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
US20030018040A1 (en) * 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
CA2129732A1 (en) * 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
AU2003244047A1 (en) 2003-09-25
IL134364A0 (en) 2001-04-30
PL343851A1 (en) 2001-09-10
KR20010033017A (ko) 2001-04-25
CA2299397A1 (en) 1999-06-24
ZA9811349B (en) 1999-06-14
HUP0100349A2 (hu) 2001-07-30
AU1306099A (en) 1999-07-05
EP1037623A1 (en) 2000-09-27
IS5385A (is) 2000-02-25
WO1999030706A1 (en) 1999-06-24
HUP0100349A3 (en) 2002-02-28
NO20002965D0 (no) 2000-06-09
BR9813539A (pt) 2000-10-10
JP2003524582A (ja) 2003-08-19
NO20002965L (no) 2000-06-09

Similar Documents

Publication Publication Date Title
EP1491193B1 (en) Therapeutic combinations comprising amlodipine and atorvastatin
AP1207A (en) Combination therapy.
EP1045691B1 (en) Statin-carboxyalkylether combinations
US20070149578A1 (en) Combination Therapy
US8557835B2 (en) Statin-carboxyalkylether combinations
NZ502874A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
US20020103252A1 (en) Statin-carboxyalkylether combinations
EP1280522B1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
EP1481962A1 (en) New cholesterolemia-lowering carboxyalkylether compound
MXPA00002105A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030225123A1 (en) Antihypertensive agents and use
MXPA00002104A (en) Carton with panel locking means
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed